[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100346816":3},{"organization":4,"outcomesModule":7,"designInfo":162,"detailedDescription":24,"studyPopulation":165,"armGroups":166,"interventions":172,"overallOfficials":177,"centralContacts":181,"locations":190,"responsibleParty":208,"collaborators":24,"id":211,"slug":24,"hasResults":212,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":24,"eligibilityCriteria":215,"healthyVolunteers":212,"sex":216,"minAge":217,"maxAge":24,"enrollmentInfo":218,"targetDuration":24,"studyType":221,"phases":24,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":193,"whyStopped":24,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},{"fullName":5,"class":6},"Nordsjaellands Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":29},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of death from any causes","Assessed through patient files","From date of admission until the day of death from any causes, up to 24 months",{"measure":14,"description":15,"timeFrame":16},"Number of participants who develop diabetes","Assessed through patient files and the national registers","Up to 24 months",[18,22,26],{"measure":19,"description":20,"timeFrame":21},"Length of hospital stay","Through patient files","Participants will be followed for the duration of hospital stay, an expected average of 5 days",{"measure":23,"description":24,"timeFrame":25},"Oral glucose tolerance test",null,"Day 1, discharge (an average of 5 days), 1 month and 6-month",{"measure":27,"description":20,"timeFrame":28},"Number of participants who are readmitted","Up to 6 months",[30,33,35,38,41,44,47,49,52,56,58,60,63,65,69,71,74,76,79,81,83,85,87,89,91,93,95,97,99,101,103,105,107,111,114,117,120,123,126,130,133,136,139,141,144,147,149,152,154,156,158,160],{"measure":31,"description":24,"timeFrame":32},"Facal sample to assess changes in microbiome","Day 1, 1 month and 6 months",{"measure":34,"description":24,"timeFrame":32},"Urine samples to assess metabolomics",{"measure":36,"description":24,"timeFrame":37},"Physical activity monitoring (measured by the AX3 accelerometers)","During admission (up to 7 days), 14 days from discharge (an average of 5 days)",{"measure":39,"description":24,"timeFrame":40},"Self-reported physical activity by scoring of the international physical activity questionnaire (IPAQ)","Day 1",{"measure":42,"description":24,"timeFrame":43},"Muscle strength (measured by hand grip test)","Day 1, discharge (an average of 5 days), 1 months and 6 months",{"measure":45,"description":24,"timeFrame":46},"Muscle strength (measured by 30-sec chair stand test)","Day 1 and discharge (an average of 5 days)",{"measure":48,"description":24,"timeFrame":46},"Functional capacity (measured by 6-minutes walking test)",{"measure":50,"description":24,"timeFrame":51},"Activities of daily living (measured by Barthel100)","Discharge (an average of 5 days)",{"measure":53,"description":54,"timeFrame":55},"BMI","Weight (kilograms) and height (cm) will be combined to report BMI in kg\u002Fm\\^2","Day 1, discharge (an average of 5 days), 1 month and 6 months",{"measure":57,"description":24,"timeFrame":55},"Waist circumference (measured in cm)",{"measure":59,"description":24,"timeFrame":55},"Body composition analysis (measured by DEXA scans)",{"measure":61,"description":24,"timeFrame":62},"Body composition analysis (measured by bioimpedance)","Daily during admission, discharge (an average of 5 days), 1 month and 6 months",{"measure":64,"description":24,"timeFrame":40},"Nutritional status (measured by NRS2002)",{"measure":66,"description":67,"timeFrame":68},"Concentration of p-phosphate (mmol\u002Fl), p-sodium (mmol\u002Fl), p-carbamide (mmol\u002Fl), p-potassium (mmol\u002Fl)","Blood sampling","Daily during admission, 1 month and 6 months",{"measure":70,"description":24,"timeFrame":62},"Concentration of pro- and anti-inflammatory cytokines (IL-6, Il-1ra, IL-18, IL-10, TNF-alpha)",{"measure":72,"description":73,"timeFrame":46},"Immune cell phenotyping to identify cell counts various T-cells, B-cells, NK-cells and monocytes","Flow cytometry on whole blood",{"measure":75,"description":67,"timeFrame":55},"Concentration of blood lipids",{"measure":77,"description":78,"timeFrame":40},"Scoring of the Charlson Comorbidity Index to predict 10-year survival","Scale ranges from 0 to 33 points to predict survival (%)",{"measure":80,"description":24,"timeFrame":40},"Oral status (determined by revised oral assessment guide)",{"measure":82,"description":24,"timeFrame":40},"Dysphagia screening (eating assessment tool 10)",{"measure":84,"description":24,"timeFrame":55},"Quality of life (EQ-5D-5L)",{"measure":86,"description":24,"timeFrame":55},"Glycemic control during oral glucose tolerance test",{"measure":88,"description":67,"timeFrame":55},"Glucagon concentration during oral glucose tolerance test",{"measure":90,"description":67,"timeFrame":55},"Insulin concentration during oral glucose tolerance test",{"measure":92,"description":67,"timeFrame":55},"C-peptide concentration during oral glucose tolerance test",{"measure":94,"description":67,"timeFrame":55},"GLP-1 concentration during oral glucose tolerance test",{"measure":96,"description":67,"timeFrame":55},"GLP-2 concentration during oral glucose tolerance test",{"measure":98,"description":67,"timeFrame":55},"GIP concentration during oral glucose tolerance test",{"measure":100,"description":24,"timeFrame":55},"Insulin sensitivity index (Matsuda) based on oral glucose tolerance test",{"measure":102,"description":24,"timeFrame":55},"Insulin secretion index based on oral glucose tolerance test",{"measure":104,"description":67,"timeFrame":68},"Concentration of galectin-3 (ng\u002Fml), sST2 (ng\u002Fml), and troponins (ng\u002Fml)",{"measure":106,"description":67,"timeFrame":68},"Concentration of NT-proBNP (ng\u002Fl)",{"measure":108,"description":109,"timeFrame":110},"Z-value of left ventricle (LV) out of echocardiography","Z-value LV","Discharge (an average of 5 days), 1 month and 6 months",{"measure":112,"description":113,"timeFrame":110},"Z-value of right ventricle (RV) out of echocardiography","Z-value RV",{"measure":115,"description":116,"timeFrame":110},"Z-value of left atrium (LA) out of echocardiography","Z-value LA",{"measure":118,"description":119,"timeFrame":110},"Shortening fraction (SF) measured in echocardiography","SF (%)",{"measure":121,"description":122,"timeFrame":110},"Ejection fraction (EF) measured in echocardiography","EF (%)",{"measure":124,"description":125,"timeFrame":110},"Valvular insufficiency measured in echocardiography","Aorta valve regurgitation, pulmonary valve regurgitation, tricuspid valve regurgitation and mitral valve regurgitation (no, minimal, moderate, severe)",{"measure":127,"description":128,"timeFrame":129},"Heart rate of 12-lead resting ECG","bpm","Daily during admission (up to 5 days)",{"measure":131,"description":132,"timeFrame":129},"Rhythm during 12-lead resting ECG","Sinus rhythm yes\u002Fno",{"measure":134,"description":135,"timeFrame":129},"Axis of the QRS complex out of the 12-lead resting ECG","Degree",{"measure":137,"description":138,"timeFrame":129},"Duration of PQ interval out of the 12-lead resting ECG","ms",{"measure":140,"description":138,"timeFrame":129},"Duration of the QRS complex out of the 12-lead resting ECG",{"measure":142,"description":15,"timeFrame":143},"Number of cardiac events","From date of admission up to 24 months",{"measure":145,"description":24,"timeFrame":146},"Sputum samples to assess glucose and lactate concentration (measured by ABL)","On admission, 1 month and 6 months",{"measure":148,"description":24,"timeFrame":146},"Sputum samples to evaluate drug resistance and O2 content",{"measure":150,"description":151,"timeFrame":51},"Forced vital capacity (FVC) during spirometry","Litre",{"measure":153,"description":151,"timeFrame":51},"Forced expiratory volume in 1 second (FEV1) during spirometry",{"measure":155,"description":24,"timeFrame":51},"FEV1% predicted during spirometry",{"measure":157,"description":24,"timeFrame":146},"Chest x-ray to image inflammation of the lungs",{"measure":159,"description":24,"timeFrame":129},"Early Warning Score (EWS) to identify patients at risk of deterioration in hospital",{"measure":161,"description":24,"timeFrame":40},"HbA1c to assess the average blood glucose levels 3 months before admission",{"allocation":24,"interventionModel":24,"interventionModelDescription":24,"primaryPurpose":24,"observationalModel":163,"timePerspective":164,"maskingInfo":24},"COHORT","PROSPECTIVE","Adults (≥18 years) admitted with community-acquired pneumonia",[167],{"label":168,"type":24,"description":169,"interventionNames":170},"Community-acquired pneumonia","Adults over 18 years old admitted with confirmed community-acquired pneumonia.",[171],"Other: No intervention",[173],{"type":6,"name":174,"description":175,"armGroupLabels":176,"otherNames":24},"No intervention","Obervational",[168],[178],{"name":179,"affiliation":5,"role":180},"Birgitte Lindegaard, Assoc. Prof","PRINCIPAL_INVESTIGATOR",[182,187],{"name":183,"role":184,"phone":185,"phoneExt":24,"email":186},"Camilla Ryrsø, MSc","CONTACT","+4548293250","camilla.koch.ryrsoe.01@regionh.dk",{"name":188,"role":184,"phone":185,"phoneExt":24,"email":189},"Maria Hegelund, MSc","maria.hein.hegelund.01@regionh.dk",[191],{"facility":192,"status":193,"city":194,"state":24,"zip":195,"country":196,"countryCode":197,"cosmosGeoPoint":198,"geoPoint":203,"contacts":204},"Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital","RECRUITING","Hillerød","3400","Denmark","DK",{"type":199,"coordinates":200},"Point",[201,202],12.30081,55.92791,{"lat":202,"lon":201},[205],{"name":206,"role":184,"phone":24,"phoneExt":24,"email":207},"Birgitte Lindegaard, MD, PhD","birgitte.lindegaard.madsen@regionh.dk",{"type":180,"investigatorFullName":209,"investigatorTitle":210,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Birgitte Lindegaard Madsen","Associated professor, MD, PhD","100346816",false,"NCT03795662","Surviving Pneumonia","Inclusion Criteria:\n\n* Infiltrate on chest radiograph plus one or more of the following:\n\n  * Fever (temperature, ≥38.0°C)\n  * Hypothermia (\\\u003C35.0°C),\n  * New cough with or without sputum production\n  * Pleuritic chest pain\n  * Dyspnea\n  * Altered breath sounds on auscultation.\n\nExclusion Criteria:\n\n* Patients unable to give informed consent\n* Patients unwilling to give informed consent","ALL","18 Years",{"count":219,"type":220},2500,"ESTIMATED","OBSERVATIONAL","The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. The main clinical outcomes of the study consist of deaths and development of diabetes.",[224],"Community-acquired Pneumonia",[168,226,227,228,229,230],"Diabetes","Immune status","Nutritional status","Physical inactivity","Risk factors","2021-04-28",{"date":233,"type":234},"2021-04-29","ACTUAL",{"date":236,"type":234},"2019-01-07",{"date":238,"type":220},"2038-12-31",{"name":5,"class":6},1]